Pulmatrix Shares Plunge 33% Ahead of Cullgen Merger and Asset Divestiture

Company Overview

PULMATRIX INCORPORATED (NASDAQ: PULM), known in Korean as 펄매트릭스, is a clinical-stage biotechnology company headquartered in Bedford, Massachusetts. The company develops inhaled therapeutics using its proprietary iSPERSE™ dry-powder delivery platform. As of December 19, 2025, PULM trades on the Nasdaq Capital Market at $2.4950 per share, representing a decrease of 32.93% over the prior session, with a trading volume of 101,125 shares.

Corporate Structure and Workforce

PULMATRIX employs a team of 11–50 individuals, who contribute expertise in drug development, regulatory affairs, and commercialization strategy. The company's organizational structure supports collaboration in clinical trial execution and business development, in accordance with Nasdaq listing requirements for corporate governance practices.

Inhaled therapeutics by Kelly Sikkema

Recent Developments and News

• April 15, 2019: Pulmatrix entered a definitive agreement with Cipla Technologies LLC for the co-development and commercialization of Pulmazole™ (PUR1900), an inhaled formulation of itraconazole targeting allergic bronchopulmonary aspergillosis in asthma patients. Cipla made a $22 million upfront payment and agreed to share development costs and future free cash flow equally.
• February 28, 2022: The company executed a 1-for-20 reverse stock split to comply with Nasdaq’s minimum bid price requirement. Outstanding shares were reduced from approximately 65.97 million to 3.30 million, while the number of authorized shares remains at 200 million.
• November 13, 2024: Pulmatrix announced a merger agreement with Cullgen Inc., a privately held clinical-stage biopharmaceutical company focused on targeted protein degradation via its uSMITE™ platform. Following the merger, pre-merger Pulmatrix stockholders are expected to hold approximately 3.6% of the combined entity, which will operate as Cullgen Inc. on Nasdaq. The transaction is anticipated to close by the end of March 2025, subject to stockholder and regulatory approvals. Prior to the closing, Pulmatrix plans to divest its iSPERSE-based assets, including the acute migraine candidate PUR3100. The combined company is projected to have approximately $65 million in cash and cash equivalents at closing, supporting operations through 2026.

Financial and Strategic Analysis

PULMATRIX’s partnership strategy, initiated with its 2019 agreement with Cipla, aims to share development risks and utilize commercial expertise. The 2022 reverse stock split was executed to maintain its public listing. In October 2025, the company filed Form 10-Q for the quarter ended September 30, detailing ongoing R&D expenditures and projected cash usage for clinical programs. On December 18, 2025, Pulmatrix submitted an 8-K current report, documenting material developments, though specifics were not disclosed in the summary. The planned merger with Cullgen signifies a shift from inhaled therapies to targeted protein degraders, while also providing a potential cash dividend to stockholders, depending on net cash exceeding $2.5 million at closing.

Market Position and Industry Context

Within the respiratory disease segment, PULMATRIX’s inhaled therapies encounter competition from established biologics and small molecules. The iSPERSE platform aims to enhance localized lung delivery and minimize systemic exposure, yet substantial capital is required for clinical advancement. The merger with Cullgen aligns PULMATRIX’s assets with Cullgen’s three degrader programs that are entering Phase 1 trials—two targeting oncology and one for managing pain—positioning the combined entity within the emerging targeted protein degradation market, which has attracted significant investment and interest from pharmaceutical partnerships.

TL;DR

Pulmatrix’s share price was $2.4950 on December 19, 2025, following a decline of 32.93%. The company is preparing to merge with Cullgen Inc. by March 2025, divesting its iSPERSE assets and offering a potential cash dividend to stockholders, provided net cash exceeds $2.5 million at closing. The merged company will be listed on Nasdaq with an estimated $65 million in cash, facilitating clinical milestones through 2026.